The latest news updates from the 2024 Symposium
Experts wrapped up the 2024 San Antonio Breast Cancer Symposium® by discussing updates from the week that may have an immediate impact for patients and physicians.
Neil Vasan, MD, PhD; Pedram Razavi, MD, PhD; Janice Tsang, MBBS, MRCP, FRCP; and Michael A. Danso, MD, highlighted recent developments across breast cancer research and care.
Panelists discussed recent U.S. Food and Drug Administration approvals, plus the importance of monitoring ovarian toxicity in breast cancer clinical trials.
Presenters focused on the mechanisms linking obesity to breast cancer risk and discussed modifiable factors such as body weight, dietary patterns, and physical activity.
Nicholas Turner, MD, PhD; Nan Chen, MD; and Pedram Razavi, MD, PhD, were among eight experts reporting results Friday during the third and final General Session of the 2024 San Antonio Breast Cancer Symposium®.
Walid Khaled, PhD, on Friday discussed work to draw a map of how the breast changes during tumorigenesis and progression.
Steffi Oesterreich, PhD, on Thursday shared highlights from her seminal fundamental and translational research on invasive lobular carcinoma.
A panel of experts on Tuesday offered guidance for patients and clinicians who have questions about the interplay of treatment and nutrition, physical activity, and sexual health.
Melissa B. Davis, PhD, on Thursday addressed the challenges of unraveling social versus biological drivers of racial disparities in cancer outcomes.
Christina Curtis, PhD, MSc, on Wednesday discussed processes that drive cancer progression across various disease stages and molecular subtypes.